Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions

Stroke. 2006 Oct;37(10):2540-5. doi: 10.1161/01.STR.0000239659.99112.fb. Epub 2006 Aug 24.

Abstract

Background and purpose: In our study we hypothesized that statins improve endothelial function in patients with lacunar infarctions (LI). Cerebral and systemic endothelial function was determined before and after 3-months treatment with atorvastatin.

Methods: Cerebral endothelial function was determined by L-arginine reactivity and systemic endothelial function by flow-mediated dilatation (FMD) in patients with LI (18 patients, aged 61.1+/-7.6 years), 20 age- and gender-matched patients with similar risk factors (SR) and 19 age- and gender-matched healthy controls. The mean arterial velocity (v(m)) in both middle cerebral arteries was measured by transcranial Doppler sonography before, during and after a 30-minute intravenous infusion of L-arginine. FMD of the brachial artery after hyperaemia was determined. The measurements were repeated after 3-months treatment with 40 mg of atorvastatin per day.

Results: L-arginine reactivity was decreased in LI patients (13.1+/-8.4%) and in patients with SR compared with healthy controls (P < or = 0.01). FMD was more impaired in patients with LI (0.06+/-4.9%) compared with patients with SR and healthy controls (P < or = 0.01). After atorvastatin treatment, L-arginine reactivity and FMD improved in both patients with LI (17.1+/-7.6%; 7.0+/-5.7%) and patients with SR (P < or = 0.01). Previously mildly increased cholesterol values normalized.

Conclusions: The decreased L-arginine reactivity and FMD improve after atorvastatin treatment in both patients with LI and patients with SR.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Arginine / pharmacology*
  • Atorvastatin
  • Blood Pressure / drug effects
  • Carbon Dioxide / blood
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / epidemiology
  • Cerebral Infarction / physiopathology*
  • Cerebrovascular Circulation / drug effects
  • Comorbidity
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Female
  • Follow-Up Studies
  • Heart Rate / drug effects
  • Hemorheology
  • Heptanoic Acids / pharmacology*
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / drug therapy
  • Male
  • Middle Aged
  • Pyrroles / pharmacology*
  • Pyrroles / therapeutic use
  • Risk Factors
  • Single-Blind Method
  • Ultrasonography, Doppler, Transcranial
  • Vasodilation / drug effects*
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology

Substances

  • Anticholesteremic Agents
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • Vasodilator Agents
  • Carbon Dioxide
  • Arginine
  • Atorvastatin